Tenaya Therapeutics Inc Interim Clinical Data from MyPEAK-1 Evaluating Safety and Early Efficacy of TN-201 in Adult Patients with MYBPC3-Associated HCM Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Yasmeen Rahimi - Piper Jaffray Inc - Analyst : Good morning, team. Congrats on the really strong data and thank you for the comparative slides that you put together. Very helpful. Team, I guess given cohort two so remarkable protein expression helps us understand with really almost tripling of the protein how we should conceptualize sort of what the clinical cardiac biomarkers and data points are potentially going to look like when you report out early next year. And obviously, it's very clear from cohort one, the longer we go, the greater the treatment response becomes. just help us conceptualize what expectations should be for cohort two. And then the next one is based on your prepared remarks, it seems like the procedural paperwork submitted to the FDA is already in process. I just want to make sure that these commentaries that were made was in regards to immunosuppression protocol for 401, and therefore there's no need for them to review the protocol for 401 just a clarification. And then the third one is, how soon can you engage with the agency on pivotal design and come back? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Question: Mike Ulves - Morgan Stanley - Analyst : Good morning, thanks for taking the question. Maybe just a follow-up on the clinical hold and sounds like you should be able to make some quick progress there, but any thoughts on when that hold could potentially be lifted? Is it weeks or is it months? And then secondly, Just prior to the hold, were you able to dose any patients in the expansion cohort at the higher dose? Just trying to get a sense of when you might get a couple more patients at that higher dose, which looks very promising. Thanks.

Question: Mike Ulves - Morgan Stanley - Analyst : Very helpful. Thank you.

Question: Joseph Pant-Guinness - HC Wainwright - Analyst : Hi, this is Sarah on for Joe. Good morning and thanks for taking the question. Also, regarding the clinical hold, just curious whether any of the patients that were dosed under your current or what will be the old immunosuppressive monitoring regimen. Will any of those need to be, you know, in terms of future analysis, will they be treated any differently, put into a separate subgroup from patients, you know, maybe added after these changes are made, or how should we think about those differences looking forward? Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Question: Joseph Pant-Guinness - HC Wainwright - Analyst : Okay, great. Thank you.

Question: Corey Jubinville - LifeSci Capital - Analyst : Hi, good morning, and congrats on the data update. questions. Can you just speak to the differences that we're seeing in left ventricular mass index versus LV posterior wall thickness? I know typically LVMI is seen as what could be an approvable endpoint in these types of cardiac indications. Posterior wall thickness demonstrated these really profound improvements, but this wasn't the case for all patients in LVMI. Intuitively, I'd anticipate that these two endpoints would be pretty lockstep with one another. I guess are there any factors in your view that would drive a robust improvement in posterior wall thickness but an increase in LVMI? And I guess in your view, is one measurement more objective or cleaner to measure, for lack of a better term? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Question: Sammy Corwin - William Blair - Analyst : Good morning. Congrats on the data, and thanks for taking my questions. FDA's clinical hold is based on the protocol uniformity. I was curious what the protocol is for using the complement inhibitor, given the laboratory signs of complement activation were seen in cohort two. And then on slide 29, you suggest that you could have multiple pivotal studies, including one in pediatrics. So I guess I was just curious if you plan on treating a pediatric patient in the MIPEAK-1 study prior to those discussions with FDA. Thank you.

Question: Sammy Corwin - William Blair - Analyst : Yeah, very helpful. Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Question: Manny Forohar - Leerink Partners - Analyst : Hey, guys. Thanks for taking the questions. I have one key one from Nate. Looking further out, there's been a lot of questions around the specific state of the programs now. More broadly, when you think about regulatory paths, we've seen from a couple of other companies in the space a mix of protein and LVMI as a co-primary endpoint. Would you expect that to be similar for you guys, or would you expect a different approach in terms of endpoint co-primary analysis as opposed to some other arrangement of the endpoint? How do you think about potential regulatory paths and endpoint construction here?

Question: Corey Jubinville - LifeSci Capital - Analyst : Yeah, it does. Thank you.

Question: Gulish Livashitz - Chardon - Analyst : Good morning. Congrats on the data again. Thanks for taking the questions. Just to follow up on some of the previous questions on the left ventricular posterior wall thickness, again, you mentioned these patients declining below that threshold associated with mortality. Can you maybe elaborate a little bit on that from your discussions with investigators or clinicians to expand on maybe the relative importance that, and the degree of risk reduction that you might see with incremental improvements there. And also, what about any other hypertrophy metrics that you're collecting? I think in the past, you may have reported data on septum thickness and things like that. So, any other metrics that we can look forward to in future updates? Thanks.